Essilor Reports Stellest 2.0 Myopia Lens Results
New interim data shows significant myopia progression reduction in children over a six-month period.
Updated on Oct. 21, 2026 in Asthma
Live Poll
Do you believe parents should pursue clinical management to slow their child's myopia progression?
EssilorLuxottica has presented interim clinical trial results for its Stellest 2.0 lenses, demonstrating that children achieved myopia progression reduction in six months comparable to one year of original lens wear. The findings were shared at a meeting of the European Society of Cataract and Refractive Surgeons.
Why it matters
Managing myopia in children is a growing health focus as early intervention can significantly reduce long-term vision impairment risks. These results provide an updated look at how lens technology can slow the physical elongation of the eye.
In a clinical trial, children wearing Stellest 2.0 lenses for six months showed 0.51 D lower myopia progression and 0.21 mm less axial elongation compared to those using single-vision lenses.
The players
EssilorLuxottica
This is a global leader in the design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses.
European Society of Cataract and Refractive Surgeons
This is a professional organization dedicated to the education and research of ophthalmic surgery.
The details
The study utilized HALT Max technology and required participants to wear the corrective lenses for at least 10 hours daily for a minimum of 6 days per week. The performance metrics at six months align with established data from original Stellest lenses, which demonstrated 0.53 D lower progression at one year.
Timeline
6 months of wear in the Stellest 2.0 clinical trial.
1 year of wear for the original Stellest lens study.
2 years of treatment effect duration for the original Stellest lens.
The Big Picture
This study extends the efficacy findings previously established by the HALT Max technology research program. It marks a continued push to validate optical interventions as a primary method for managing pediatric myopia progression.
Parents and patients should note that while these lenses show promise in clinical settings, their availability remains subject to local regulatory approval. Daily adherence of at least 10 hours is necessary to achieve the performance levels observed in the study.
The takeaway
Clinical evidence continues to support the use of specialized lenses in slowing the progression of myopia during childhood. Patients should consult with an eye care professional to discuss the latest options for vision management.
Further reading
For more information on eye health treatments, visit Asthma.
Live Poll
Do you believe parents should pursue clinical management to slow their child's myopia progression?
